Fraser has over 20 years experience in the pharmaceutical industry, ranging from small start up biotech to large multinational pharmaceutical companies.  Fraser began his career with Merck & Co. at their Neuroscience Research Centre in the UK working on a range of neurodegeneration and psychiatry projects. He then moved to AstraZeneca's Respiratory and Inflammation research group where he worked on osteoarthritis, rheumatoid arthritis and pain.  In 2011 he took a role with Shire where he was a Senior Director and had responsibility for Discovery Biology for Shire's CNS and GI discovery portfolio. In addition to his role with Arisgen, Fraser is also Vice President of Biology at Calcico Therapeutics, a venture backed spin out from the University of Oxford. Fraser is also a Co-founder and Director of Polleo Pharma, a spin out company from Shire looking to develop leading therapies for behavioural health disorders. Fraser obtained his BSc in Immunology and Pharmacology from the University of Strathclyde, his PhD in Neuropharmacology from the School of Pharmacy, University of London and his MBA from Manchester Business School, University of Manchester.

 pharmaceutical industry